Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL
oncoprotein, presents its treatment based on tyrosine kinase inhibitors (TKIs), mainly imatinib. However, despite its
clinical success, almost 30% of all CML patients demand alternative therapy. In this context, the development of drugs
capable of overcoming TKIs resistance is imperative. The pterocarpanquinone-LQB-118 is a novel compound with
anti-tumor effect in CML cells whose mechanism of action is being elucidated. Here, we demonstrate that in two CML cell lines
exhibiting different biological characteristics, LQB-118 modulates NFκB subcellular localization, apparently independently of the AKT
and MAPK pathways, partially inhibits proteasome activity, and alters the expression of microRNAs -9 and -21.
Keywords: Cancer, chronic myeloid leukemia, microRNA, multidrug resistance phenotype, NFκB, pterocarpanquinone-LQB-118.
Rights & PermissionsPrintExport